Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Literature DB >> 27332911

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Flora Peyvandi, Filip Callewaert.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27332911 DOI： 10.1056/NEJMc1603180

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

6 in total

Review 1. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

Authors: Roghaye Arezumand; Abbas Alibakhshi; Javad Ranjbari; Ali Ramazani; Serge Muyldermans
Journal: Front Immunol Date: 2017-12-08 Impact factor: 7.561

2. Cellular stress induces erythrocyte assembly on intravascular von Willebrand factor strings and promotes microangiopathy.

Authors: Jan P Nicolay; Verena Thorn; Christoph Daniel; Kerstin Amann; Balasaheb Siraskar; Florian Lang; Carina Hillgruber; Tobias Goerge; Stefan Hoffmann; Christian Gorzelanny; Volker Huck; Christian Mess; Tobias Obser; Reinhard Schneppenheim; Ingrid Fleming; Matthias F Schneider; Stefan W Schneider
Journal: Sci Rep Date: 2018-07-19 Impact factor: 4.379

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Review 1. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

2. Cellular stress induces erythrocyte assembly on intravascular von Willebrand factor strings and promotes microangiopathy.

3. Rapid Delivery of Nanobodies/V_HHs into Living Cells via Expressing In Vitro-Transcribed mRNA.

4. Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.

Review 5. ADAMTS-13 and von Willebrand factor: a dynamic duo.

Review 6. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Review 1. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

2. Cellular stress induces erythrocyte assembly on intravascular von Willebrand factor strings and promotes microangiopathy.

3. Rapid Delivery of Nanobodies/VHHs into Living Cells via Expressing In Vitro-Transcribed mRNA.

4. Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era.

Review 5. ADAMTS-13 and von Willebrand factor: a dynamic duo.

Review 6. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.

3. Rapid Delivery of Nanobodies/V_HHs into Living Cells via Expressing In Vitro-Transcribed mRNA.